ShanXi C&Y Pharmaceutical Group Co., Ltd. reported earnings results for the full year ended December 31, 2022. For the full year, the company reported sales was CNY 824.84 million compared to CNY 924.94 million a year ago. Revenue was CNY 829 million compared to CNY 930.37 million a year ago.

Net loss was CNY 118.57 million compared to CNY 91.44 million a year ago. Basic loss per share from continuing operations was CNY 0.5002 compared to CNY 0.4011 a year ago. Diluted loss per share from continuing operations was CNY 0.5002 compared to CNY 0.4011 a year ago.